{
  "success": true,
  "pagesUsed": [
    5,
    6,
    7,
    31,
    32,
    33,
    39,
    40,
    41,
    42,
    43
  ],
  "modelUsed": "claude-opus-4-5",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Histological or cytological confirmation of cancer",
        "text": "Have histological or cytological confirmation of cancer.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Refractory/relapsed solid tumors",
        "text": "Have refractory/relapsed solid tumors and have exhausted all treatments with proven clinical benefit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Measurable disease",
        "text": "Have measurable disease as defined by RECIST v1.1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "ECOG performance status",
        "text": "Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Life expectancy",
        "text": "Have a life expectancy of at least 12 weeks.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Adequate organ function",
        "text": "Have adequate organ function as defined by protocol-specified laboratory values.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Recovery from prior therapy toxicities",
        "text": "Have resolution of all clinically significant toxic effects of prior cancer therapy to Grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Urinary protein requirement",
        "text": "Have urinary protein ≤1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates proteinuria ≥2+, a 24-hour urine for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Sex",
        "text": "Male or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to refrain from donating sperm and either be abstinent from heterosexual or homosexual intercourse or agree to use a male condom and female partner use of an additional highly effective contraceptive method during the intervention period and for at least 84 days/12 weeks following completion of study drug administration. Female participants are eligible if not pregnant or breastfeeding, and either not a woman of childbearing potential (WOCBP) or is a WOCBP using a highly effective contraceptive method during the intervention period and for at least 84 days/12 weeks after the last dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Informed Consent",
        "text": "Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Uncontrolled hypertension",
        "text": "Have uncontrolled hypertension defined as systolic blood pressure (BP) >150 mmHg or diastolic BP >90 mmHg despite standard medical management.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Significant bleeding disorders",
        "text": "Have significant bleeding disorders or experienced Grade 3/4 GI bleeding within 3 months prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Hepatic impairment",
        "text": "Have hepatic impairment (such as severe liver cirrhosis Child-Pugh B [or worse], cirrhosis with a history of hepatic encephalopathy, clinically meaningful ascites requiring ongoing treatment with diuretics and/or paracentesis, or history of hepatorenal syndrome).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Arterial thromboembolic events",
        "text": "Have experienced any arterial thromboembolic events (ATEs), including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, ≤6 months prior to randomization.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Congestive heart failure or cardiac arrhythmia",
        "text": "The participant has clinically relevant congestive heart failure (CHF; New York Heart Association [NYHA] Grade ≥2) or symptomatic or poorly controlled cardiac arrhythmia.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Serious concomitant systemic disorder",
        "text": "Have a serious concomitant systemic disorder that, in the opinion of the investigator, would preclude participation in the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Active infection requiring systemic therapy",
        "text": "Have active infection requiring systemic therapy (e.g., bacterial infection requiring intravenous antibiotics at time of initiating study treatment, systemic fungal infection, or detectable viral infection requiring systemic therapy).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "HIV positive participants",
        "text": "Human immunodeficiency virus (HIV) positive participants (HIV 1 and/or 2; screening not required) are excluded unless they are well controlled on highly active antiretroviral therapy with: a. No evidence of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 2 years, and b. CD4 count >350 cells/μl.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Chronic active hepatitis B or C",
        "text": "Have chronic active hepatitis B or C virus infection (screening not required).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Prior or second concurrent primary malignancies",
        "text": "Have prior or second concurrent primary malignancies that, in the judgment of the investigator and the Lilly clinical research physician (CRP)/clinical research scientist (CRS), may affect the interpretation of results. Participants with carcinoma in situ of any origin and participants with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma), as judged by the Lilly CRP/CRS, are eligible for this study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Symptomatic CNS malignancy or metastasis",
        "text": "Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required). Participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids (exceeding 10 mg/day prednisone or equivalent) and/or anticonvulsants to treat CNS metastases, and their disease is asymptomatic and radiographically stable for at least 30 days.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "History of GI perforation and/or fistula",
        "text": "Have a history of GI perforation and/or fistula within 6 months prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Serious or non-healing wound, ulcer, or bone fracture",
        "text": "Serious or non-healing wound, ulcer, or bone fracture within 4 weeks prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Chronic therapy with NSAIDs or antiplatelet agents",
        "text": "Are receiving chronic therapy with nonsteroidal anti-inflammatory agents (e.g., indomethacin, naproxen, or similar agents) or other antiplatelet agents (e.g., clopidogrel or dipyridamole) within 7 days prior to first dose of study treatment. Aspirin use at doses up to 325 mg/day is permitted (see Section 10.6, Appendix 6).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Prior treatment with IV ramucirumab",
        "text": "Participants with prior treatment with IV ramucirumab as monotherapy or in combination with chemotherapy or targeted/biological agents on or outside of a clinical trial.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Recent participation in clinical study with investigational product",
        "text": "Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed. Exceptions will be considered on a case by case basis by the sponsor CRP/CRS.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Tattoos or scars over abdomen interfering with injection site assessments",
        "text": "Have tattoos or scars over the abdomen, or other factors (e.g., rash, excessive folds of skin) that, in the investigator's opinion, would interfere with injection site assessments.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Elective or planned major surgery",
        "text": "Have an elective or a planned major surgery during the course of the trial, or have undergone major surgery within 28 days prior to enrollment. Note: Central venous access device placement must occur at least 7 days prior to enrollment. Note: If participant received major surgery, the participant must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Major blood vessel invasion or encasement by cancer (NSCLC)",
        "text": "Have radiologically documented evidence of major blood vessel invasion or encasement by cancer.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Intratumor cavitation (NSCLC)",
        "text": "Have radiographic evidence of intratumor cavitation, regardless of tumor histology.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "History of gross hemoptysis (NSCLC)",
        "text": "Have a history of gross hemoptysis (defined as bright red blood or ≥1/2 teaspoon) within 2 months prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Histological or cytological confirmation of cancer",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "Refractory/relapsed solid tumors",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "Measurable disease",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "ECOG performance status",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "Life expectancy",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "Adequate organ function",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "Recovery from prior therapy toxicities",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "Urinary protein requirement",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Sex",
        "previousId": "ec_8",
        "nextId": "ec_10"
      },
      {
        "id": "ec_10",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion",
        "name": "Informed Consent",
        "previousId": "ec_9"
      },
      {
        "id": "ec_11",
        "identifier": "11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion",
        "name": "Uncontrolled hypertension",
        "nextId": "ec_12"
      },
      {
        "id": "ec_12",
        "identifier": "12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion",
        "name": "Significant bleeding disorders",
        "previousId": "ec_11",
        "nextId": "ec_13"
      },
      {
        "id": "ec_13",
        "identifier": "13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion",
        "name": "Hepatic impairment",
        "previousId": "ec_12",
        "nextId": "ec_14"
      },
      {
        "id": "ec_14",
        "identifier": "14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion",
        "name": "Arterial thromboembolic events",
        "previousId": "ec_13",
        "nextId": "ec_15"
      },
      {
        "id": "ec_15",
        "identifier": "15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion",
        "name": "Congestive heart failure or cardiac arrhythmia",
        "previousId": "ec_14",
        "nextId": "ec_16"
      },
      {
        "id": "ec_16",
        "identifier": "16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion",
        "name": "Serious concomitant systemic disorder",
        "previousId": "ec_15",
        "nextId": "ec_17"
      },
      {
        "id": "ec_17",
        "identifier": "17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion",
        "name": "Active infection requiring systemic therapy",
        "previousId": "ec_16",
        "nextId": "ec_18"
      },
      {
        "id": "ec_18",
        "identifier": "18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion",
        "name": "HIV positive participants",
        "previousId": "ec_17",
        "nextId": "ec_19"
      },
      {
        "id": "ec_19",
        "identifier": "19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion",
        "name": "Chronic active hepatitis B or C",
        "previousId": "ec_18",
        "nextId": "ec_20"
      },
      {
        "id": "ec_20",
        "identifier": "20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion",
        "name": "Prior or second concurrent primary malignancies",
        "previousId": "ec_19",
        "nextId": "ec_21"
      },
      {
        "id": "ec_21",
        "identifier": "21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion",
        "name": "Symptomatic CNS malignancy or metastasis",
        "previousId": "ec_20",
        "nextId": "ec_22"
      },
      {
        "id": "ec_22",
        "identifier": "22",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion",
        "name": "History of GI perforation and/or fistula",
        "previousId": "ec_21",
        "nextId": "ec_23"
      },
      {
        "id": "ec_23",
        "identifier": "23",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion",
        "name": "Serious or non-healing wound, ulcer, or bone fracture",
        "previousId": "ec_22",
        "nextId": "ec_24"
      },
      {
        "id": "ec_24",
        "identifier": "24",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion",
        "name": "Chronic therapy with NSAIDs or antiplatelet agents",
        "previousId": "ec_23",
        "nextId": "ec_25"
      },
      {
        "id": "ec_25",
        "identifier": "25",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion",
        "name": "Prior treatment with IV ramucirumab",
        "previousId": "ec_24",
        "nextId": "ec_26"
      },
      {
        "id": "ec_26",
        "identifier": "26",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion",
        "name": "Recent participation in clinical study with investigational product",
        "previousId": "ec_25",
        "nextId": "ec_27"
      },
      {
        "id": "ec_27",
        "identifier": "27",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion",
        "name": "Tattoos or scars over abdomen interfering with injection site assessments",
        "previousId": "ec_26",
        "nextId": "ec_28"
      },
      {
        "id": "ec_28",
        "identifier": "28",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion",
        "name": "Elective or planned major surgery",
        "previousId": "ec_27",
        "nextId": "ec_29"
      },
      {
        "id": "ec_29",
        "identifier": "29",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion",
        "name": "Major blood vessel invasion or encasement by cancer (NSCLC)",
        "previousId": "ec_28",
        "nextId": "ec_30"
      },
      {
        "id": "ec_30",
        "identifier": "30",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion",
        "name": "Intratumor cavitation (NSCLC)",
        "previousId": "ec_29",
        "nextId": "ec_31"
      },
      {
        "id": "ec_31",
        "identifier": "31",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion",
        "name": "History of gross hemoptysis (NSCLC)",
        "previousId": "ec_30"
      }
    ],
    "summary": {
      "inclusionCount": 10,
      "exclusionCount": 21,
      "totalCount": 31
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Histological or cytological confirmation of cancer",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "Refractory/relapsed solid tumors",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "Measurable disease",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "ECOG performance status",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "Life expectancy",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "Adequate organ function",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "Recovery from prior therapy toxicities",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "Urinary protein requirement",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Sex",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_10",
        "name": "Informed Consent",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_11",
        "name": "Uncontrolled hypertension",
        "identifier": "11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_12",
        "name": "Significant bleeding disorders",
        "identifier": "12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_13",
        "name": "Hepatic impairment",
        "identifier": "13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_14",
        "name": "Arterial thromboembolic events",
        "identifier": "14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_15",
        "name": "Congestive heart failure or cardiac arrhythmia",
        "identifier": "15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_16",
        "name": "Serious concomitant systemic disorder",
        "identifier": "16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_17",
        "name": "Active infection requiring systemic therapy",
        "identifier": "17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_18",
        "name": "HIV positive participants",
        "identifier": "18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_19",
        "name": "Chronic active hepatitis B or C",
        "identifier": "19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_20",
        "name": "Prior or second concurrent primary malignancies",
        "identifier": "20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_21",
        "name": "Symptomatic CNS malignancy or metastasis",
        "identifier": "21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_22",
        "name": "History of GI perforation and/or fistula",
        "identifier": "22",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_23",
        "name": "Serious or non-healing wound, ulcer, or bone fracture",
        "identifier": "23",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_24",
        "name": "Chronic therapy with NSAIDs or antiplatelet agents",
        "identifier": "24",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_25",
        "name": "Prior treatment with IV ramucirumab",
        "identifier": "25",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_26",
        "name": "Recent participation in clinical study with investigational product",
        "identifier": "26",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_27",
        "name": "Tattoos or scars over abdomen interfering with injection site assessments",
        "identifier": "27",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_28",
        "name": "Elective or planned major surgery",
        "identifier": "28",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_29",
        "name": "Major blood vessel invasion or encasement by cancer (NSCLC)",
        "identifier": "29",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_30",
        "name": "Intratumor cavitation (NSCLC)",
        "identifier": "30",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_31",
        "name": "History of gross hemoptysis (NSCLC)",
        "identifier": "31",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Histological or cytological confirmation of cancer",
        "text": "Have histological or cytological confirmation of cancer.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Refractory/relapsed solid tumors",
        "text": "Have refractory/relapsed solid tumors and have exhausted all treatments with proven clinical benefit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Measurable disease",
        "text": "Have measurable disease as defined by RECIST v1.1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "ECOG performance status",
        "text": "Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Life expectancy",
        "text": "Have a life expectancy of at least 12 weeks.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Adequate organ function",
        "text": "Have adequate organ function as defined by protocol-specified laboratory values.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Recovery from prior therapy toxicities",
        "text": "Have resolution of all clinically significant toxic effects of prior cancer therapy to Grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Urinary protein requirement",
        "text": "Have urinary protein ≤1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates proteinuria ≥2+, a 24-hour urine for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Sex",
        "text": "Male or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to refrain from donating sperm and either be abstinent from heterosexual or homosexual intercourse or agree to use a male condom and female partner use of an additional highly effective contraceptive method during the intervention period and for at least 84 days/12 weeks following completion of study drug administration. Female participants are eligible if not pregnant or breastfeeding, and either not a woman of childbearing potential (WOCBP) or is a WOCBP using a highly effective contraceptive method during the intervention period and for at least 84 days/12 weeks after the last dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Informed Consent",
        "text": "Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Uncontrolled hypertension",
        "text": "Have uncontrolled hypertension defined as systolic blood pressure (BP) >150 mmHg or diastolic BP >90 mmHg despite standard medical management.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Significant bleeding disorders",
        "text": "Have significant bleeding disorders or experienced Grade 3/4 GI bleeding within 3 months prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Hepatic impairment",
        "text": "Have hepatic impairment (such as severe liver cirrhosis Child-Pugh B [or worse], cirrhosis with a history of hepatic encephalopathy, clinically meaningful ascites requiring ongoing treatment with diuretics and/or paracentesis, or history of hepatorenal syndrome).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Arterial thromboembolic events",
        "text": "Have experienced any arterial thromboembolic events (ATEs), including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, ≤6 months prior to randomization.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Congestive heart failure or cardiac arrhythmia",
        "text": "The participant has clinically relevant congestive heart failure (CHF; New York Heart Association [NYHA] Grade ≥2) or symptomatic or poorly controlled cardiac arrhythmia.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Serious concomitant systemic disorder",
        "text": "Have a serious concomitant systemic disorder that, in the opinion of the investigator, would preclude participation in the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Active infection requiring systemic therapy",
        "text": "Have active infection requiring systemic therapy (e.g., bacterial infection requiring intravenous antibiotics at time of initiating study treatment, systemic fungal infection, or detectable viral infection requiring systemic therapy).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "HIV positive participants",
        "text": "Human immunodeficiency virus (HIV) positive participants (HIV 1 and/or 2; screening not required) are excluded unless they are well controlled on highly active antiretroviral therapy with: a. No evidence of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 2 years, and b. CD4 count >350 cells/μl.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Chronic active hepatitis B or C",
        "text": "Have chronic active hepatitis B or C virus infection (screening not required).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Prior or second concurrent primary malignancies",
        "text": "Have prior or second concurrent primary malignancies that, in the judgment of the investigator and the Lilly clinical research physician (CRP)/clinical research scientist (CRS), may affect the interpretation of results. Participants with carcinoma in situ of any origin and participants with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma), as judged by the Lilly CRP/CRS, are eligible for this study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Symptomatic CNS malignancy or metastasis",
        "text": "Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required). Participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids (exceeding 10 mg/day prednisone or equivalent) and/or anticonvulsants to treat CNS metastases, and their disease is asymptomatic and radiographically stable for at least 30 days.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "History of GI perforation and/or fistula",
        "text": "Have a history of GI perforation and/or fistula within 6 months prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Serious or non-healing wound, ulcer, or bone fracture",
        "text": "Serious or non-healing wound, ulcer, or bone fracture within 4 weeks prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Chronic therapy with NSAIDs or antiplatelet agents",
        "text": "Are receiving chronic therapy with nonsteroidal anti-inflammatory agents (e.g., indomethacin, naproxen, or similar agents) or other antiplatelet agents (e.g., clopidogrel or dipyridamole) within 7 days prior to first dose of study treatment. Aspirin use at doses up to 325 mg/day is permitted (see Section 10.6, Appendix 6).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Prior treatment with IV ramucirumab",
        "text": "Participants with prior treatment with IV ramucirumab as monotherapy or in combination with chemotherapy or targeted/biological agents on or outside of a clinical trial.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Recent participation in clinical study with investigational product",
        "text": "Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed. Exceptions will be considered on a case by case basis by the sponsor CRP/CRS.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Tattoos or scars over abdomen interfering with injection site assessments",
        "text": "Have tattoos or scars over the abdomen, or other factors (e.g., rash, excessive folds of skin) that, in the investigator's opinion, would interfere with injection site assessments.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Elective or planned major surgery",
        "text": "Have an elective or a planned major surgery during the course of the trial, or have undergone major surgery within 28 days prior to enrollment. Note: Central venous access device placement must occur at least 7 days prior to enrollment. Note: If participant received major surgery, the participant must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Major blood vessel invasion or encasement by cancer (NSCLC)",
        "text": "Have radiologically documented evidence of major blood vessel invasion or encasement by cancer.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Intratumor cavitation (NSCLC)",
        "text": "Have radiographic evidence of intratumor cavitation, regardless of tumor histology.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "History of gross hemoptysis (NSCLC)",
        "text": "Have a history of gross hemoptysis (defined as bright red blood or ≥1/2 teaspoon) within 2 months prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedSex": [
        {
          "code": "Male",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Male"
        },
        {
          "code": "Female",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Female"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}